The legend of cytomegalovirus and glioblastoma lives on

Weller, M; Soffietti, R; Brada, M

DOI: https://doi.org/10.1093/neuonc/not204

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-95398
Accepted Version

Originally published at:
DOI: https://doi.org/10.1093/neuonc/not204
LETTER TO THE EDITOR

The legend of CMV and glioblastoma lives on

Michael Weller, MD
Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland

Riccardo Soffietti, MD
Department of Neuro-Oncology, University Hospital Turin, Via Cherasco 15, 10126 Turin, Italy

Michael Brada, MD
Leaders in Oncology Care, 95 Harley Street, London, W1G 6AF, Great Britain

Running title: CMV and glioblastoma

Key words: CMV, valganciclovir, glioblastoma, bias, trial

The authors indicate no conflict of interest and report no funding for this study.
The quest to find effective treatments in glioblastoma, with the exception of one agent in 20 years, continues to fail. One reason is parading ineffective treatments as “promising” based on flawed studies.

An underpowered randomized Phase II study of valganciclovir demonstrated lack of efficacy\(^1\) and yet, a biased retrospective analysis subselecting favourable patients gets unwarranted publicity, in the *New England Journal of Medicine*\(^2\). Improved survival is claimed for newly assembled 50 valganciclovir patients, consisting of 22 from the experimental arm\(^1\), 8 cross-over patients from the control arm\(^1\) (i.e. those that did well enough to make the cross-over), and 20 odd patients treated outside a trial at the same institution.\(^2\) In all patients valganciclovir was only given “when there was no evidence of progression” (i.e. good prognosis patients). These were compared with a poorly characterized “contemporary control” group.

Looking at CMV as a target may be reasonable, but to demonstrate efficacy of anti-CMV strategies in glioblastoma needs well designed prospective studies avoiding claims which are potentially misleading. On current evidence there is no justification to expose glioblastoma patients to valganciclovir outside a clinical trial.

References